KAYPRIL

This brand name is authorized in Nigeria.

Active ingredients

The drug KAYPRIL contains one active pharmaceutical ingredient (API):

`1`	Lisinopril UNII `E7199S1YWR` - LISINOPRIL
	Lisinopril is a peptidyl dipeptidase inhibitor. It inhibits the angiotensin-converting enzyme (ACE) that catalyses the conversion of angiotensin I to the vasoconstrictor peptide, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex. Inhibition of ACE results in decreased concentrations of angiotensin II which results in decreased vasopressor activity and reduced aldosterone secretion.
	Read more about Lisinopril

Packages

This drug has been approved in Nigeria as follows:

Identifier	Form	Presentation	Description	Approval
C4-1847	Tablet	Kaypril 5 Tablet TAB 5 mg 3 x 10's	Tablet	28/09/2021
C4-1848	Tablet	Kaypril 10 Tablet TAB 10 mg 3 x 10's	Tablet	28/09/2021

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
NG	Registered Drug Product Database	C4-1847, C4-1848

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.